Merck
CN
  • Early Phase Arterial Reaction Following Drug-Eluting and Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction.

Early Phase Arterial Reaction Following Drug-Eluting and Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction.

International heart journal (2015-06-30)
Ryo Nishio, Toshiro Shinke, Yoshihiro Morino, Kengo Tanabe, Jungo Furuya, Kaname Takizawa, Junya Ako, Ken Kozuma, Kiyoshi Hibi, Hideki Ishii, Atsushi Hirohata, Yoritaka Otsuka, Hiromasa Otake, Tomofumi Takaya, Ken-Ichi Hirata
摘要

The early phase arterial reaction after implantation of second-generation drug-eluting stents (2nd DES) and baremetal stents (BMS) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear.The MECHANISM pilot study is a multi-center prospective registry that enrolled 24 STEMI patients (from 11 centers) who had undergone implantation of everolimus-eluting (n = 6), biolimus A9-eluting (n = 6) or zotarolimus-eluting stents (n = 6), or BMS (n = 6). Scheduled optical coherence tomography (OCT) was performed 2 weeks after implantation, and images were independently analyzed at a core laboratory in a blinded fashion. Intra-stent thrombus was quantitatively analyzed in terms of the maximal area and the percentage of cross-sections with thrombus (the numbers of cross-section with thrombus × 100 divided by total number of cross-sections within the stented segment). More than 90% of struts were already covered 2 weeks after the index procedure, regardless of the stent type. There were no differences in stent diameter, minimal lumen diameter, minimal lumen area, neointimal thickness, or the frequencies of malapposed and uncovered struts among the 4 groups. The quantity of intra-stent thrombus also did not differ among the 4 groups.The results of this pilot study suggest that the 2-week vascular responses seem to be similar among 2nd DES and BMS in STEMI patients. Considering the possible advantage of 2nd DES in the prevention of restenosis, 2nd DES are a feasible option for the treatment of patients with STEMI.

材料
货号
品牌
产品描述

Sigma-Aldrich
N,N-双(2-羟乙基)-2-氨基乙磺酸, ≥99.0% (titration)
Sigma-Aldrich
Suplatast tosylate, ≥98% (HPLC)
Sigma-Aldrich
N,N-双(2-羟乙基)-2-氨基乙磺酸, Vetec, reagent grade, ≥99%